CYP7A1 polymorphism influences the LDL cholesterol-lowering response to atorvastatin

Journal of Clinical Pharmacy and Therapeutics

Volumn 37, Issue 6, 2012, Pages 719-723

  Jiang, X Y ^a   Zhang, Q ^b   Chen, P ^c   Li, S Y ^d   Zhang, N N ^c   Chen, X D ^d   Wang, G C ^c   Wang, H B ^a   Zhuang, M Q ^c   Lu, M ^c  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b HEBEI MEDICAL UNIVERSITY   (China)

^c SHANDONG UNIVERSITY   (China)

^d FUDAN UNIVERSITY   (China)

Author keywords

atorvastatin; CYP7A1; gene; pharmacogenetics

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER G5; ATORVASTATIN; CHOLESTEROL 7ALPHA MONOOXYGENASE; CYTOCHROME P450 3A5; LOW DENSITY LIPOPROTEIN CHOLESTEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHINESE; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

AGED; ATP-BINDING CASSETTE TRANSPORTERS; CHINA; CHOLESTEROL 7-ALPHA-HYDROXYLASE; CHOLESTEROL, LDL; CYTOCHROME P-450 CYP3A; FEMALE; GENETIC VARIATION; GENOTYPE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PYRROLES;

EID: 84868370256     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2012.01372.x     Document Type: Article

References (24)

1. Weinshilboum R,. Inheritance and drug response. N Engl J Med, 2003; 348: 529-537.
2. Evans WE, McLeod H,. Pharmacogenomics drug disposition, drug targets, and side effects. N Engl J Med, 2003; 348: 538-549.
3. Vaughan CJ, Gotto AM Jr,. Update on statins: 2003. Circulation, 2004; 110: 886-892.
4. Lennernas H,. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet, 2003; 42: 1141-1160.
5. Yu L, Hammer RE, Li-Hawkins J, Von Bergmann K, Lutjohann D, Cohen JC, Hobbs HH,. Disruption of Abcg5 and Abcg8 in mice reveals their crucial role in biliary cholesterol secretion. Proc Natl Acad Sci USA, 2002; 99: 16237-16242.
6. Gilardi F, Mitro N, Godio C, Scotti E, Caruso D, Crestani M, De Fabiani E,. The pharmacological exploitation of cholesterol 7alpha-hydroxylase, the key enzyme in bile acid synthesis: from binding resins to chromatin remodelling to reduce plasma cholesterol. Pharmacol Ther, 2007; 116: 449-472.
7. Johnson GC, Esposito L, Barratt BJ, et al. Haplotype tagging for the identification of common disease genes. Nat Genet, 2001; 29: 233-237.
8. Stephens M, Smith NJ, Donnelly P,. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet, 2001; 68: 978-989.
9. Srivastava A, Garg N, Srivastava A, Srivastava K, Mittal B,. Effect of genetic variant (rs11887534) in ABCG8 gene in coronary artery disease and response to atorvastatin therapy. Life Sci, 2010; 28: 307-313.
10. Couture P, Otvos JD, Cupples LA, Wilson PW, Schaefer EJ, Ordovas JM,. Association of the A-204C polymorphism in the cholesterol 7alpha-hydroxylase gene with variations in plasma low density lipoprotein cholesterol levels in the Framingham Offspring Study. J Lipid Res, 1999; 40: 1883-1889.
11. Boom R, Sol CJ, Salimans MM, Jansen CL, Wertheim-van Dillen PM, van der Noordaa J,. Rapid and simple method for purification of nucleic acids. J Clin Microbiol, 1990; 28: 495-503.
12. Pinsonneault J, Nielsen CU, Sadée W,. Genetic variants of the human H+/dipeptide transporter PEPT2: analysis of haplotype functions. J Pharmacol Exp Ther, 2004; 311: 1088-1096.
13. Kajinami K, Takekoshi N, Brousseau ME, Ordovas JM, Schaefer EJ,. Additive gene-gene interaction between CYP7A1 and APOE as genetic determinants of LDL cholesterol-lowering response to atorvastatin (abstract). J Am Coll Cardiol, 2004; 43 (Suppl. A): 505A.
14. Lio D, Marino V, Serauto A, et al. Genotype frequencies of the +874TA single nucleotide polymorphism in the first intron of the interferon-gamma gene in a sample of Sicilian patients affected by tuberculosis. Eur J Immunogenet, 2002; 29: 371-374.
15. Tokuhiro S, Yamada R, Chang X, et al. An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis. Nat Genet, 2003; 35: 341-348.
16. Berge KE, von Bergmann K, Lutjohann D, Guerra R, Grundy SM, Hobbs HH, Cohen JC,. Heritability of plasma noncholesterol sterols and relationship to DNA sequence polymorphism in ABCG5 and ABCG8. J Lipid Res, 2002; 43: 486-494.
17. Gylling H, Hallikainen M, Pihlajamäki J, et al. Polymorphisms in the ABCG5 and ABCG8 gene associate with cholesterol absorption and insulin sensitivity. J Lipid Res, 2004; 45: 1660-1665.
18. Lu Y, Feskens EJ, Boer JM, Müller M,. The potential influence of genetic variants in genes along bile acid and bile metabolic pathway on blood cholesterol levels in the population. Atherosclerosis, 2010; 204: 453-458.
19. Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ,. Interactions between common genetic polymorphisms in ABCG5/G8 and CYP7A1 on LDL cholesterol-lowering response to atorvastatin. Atherosclerosis, 2004; 175: 287-293.
20. Kajinami K, Brousseau ME, Nartsupha C, Ordovas JM, Schaefer EJ,. ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin. J Lipid Res, 2004; 45: 653-656.
21. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet, 2001; 27: 383-391.
22. Kivistö KT, Niemi M, Schaeffeler E, et al. Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics, 2004; 14: 523-525.
23. Willrich MA, Hirata MH, Genvigir FD, et al. CYP3A5 3A allele is associated with reduced lowering-lipid response to Atorvastatin in individuals with hypercholesterolemia. Clin Chim Acta, 2008; 398: 15-20.
24. Fiegenbaum M, da Silveira FR, Van der Sand CR, Van der Sand LC, Ferreira ME, Pires RC, Hutz MH,. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin Pharmacol Ther, 2005; 78: 551-558.